114 related articles for article (PubMed ID: 9127399)
1. Effects of an angiotensin II antagonist on reperfusion arrhythmias in dogs.
Matsuo K; Kumagai K; Annoura M; Yamanouchi Y; Handa K; Nakashima Y; Hiroki T; Arakawa K
Pacing Clin Electrophysiol; 1997 Apr; 20(4 Pt 1):938-45. PubMed ID: 9127399
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion.
Zhu B; Sun Y; Sievers RE; Browne AE; Pulukurthy S; Sudhir K; Lee RJ; Chou TM; Chatterjee K; Parmley WW
J Am Coll Cardiol; 2000 Mar; 35(3):787-95. PubMed ID: 10716484
[TBL] [Abstract][Full Text] [Related]
3. EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction.
Lynch JJ; Stump GL; Wallace AA; Painter CA; Thomas JM; Kusma SE; Gould RJ; Grossman W
J Am Coll Cardiol; 1999 Sep; 34(3):876-84. PubMed ID: 10483973
[TBL] [Abstract][Full Text] [Related]
4. Reperfusion-induced arrhythmias are suppressed by inhibition of the angiotensin II type 1 receptor.
Yahiro E; Ideishi M; Wang LX; Urata H; Kumagai K; Arakawa K; Saku K
Cardiology; 2003; 99(2):61-7. PubMed ID: 12711879
[TBL] [Abstract][Full Text] [Related]
5. Effects of captopril and losartan on myocardial ischemia-reperfusion induced arrhythmias and necrosis in rats.
Ozer MK; Sahna E; Birincioglu M; Acet A
Pharmacol Res; 2002 Apr; 45(4):257-63. PubMed ID: 12030787
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat.
Schieffer B; Wirger A; Meybrunn M; Seitz S; Holtz J; Riede UN; Drexler H
Circulation; 1994 May; 89(5):2273-82. PubMed ID: 8181153
[TBL] [Abstract][Full Text] [Related]
7. Losartan attenuates myocardial ischemia-induced ventricular arrythmias and reperfusion injury in spontaneously hypertensive rats.
Lee YM; Peng YY; Ding YA; Yen MH
Am J Hypertens; 1997 Aug; 10(8):852-8. PubMed ID: 9270079
[TBL] [Abstract][Full Text] [Related]
8. Effects of angiotensin II type 1 receptor antagonist (candesartan) in preventing fatal ventricular arrhythmias in dogs during acute myocardial ischemia and reperfusion.
Hiura N; Wakatsuki T; Yamamoto T; Nishikado A; Oki T; Ito S
J Cardiovasc Pharmacol; 2001 Nov; 38(5):729-36. PubMed ID: 11602819
[TBL] [Abstract][Full Text] [Related]
9. Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale.
Kiely DG; Cargill RI; Wheeldon NM; Coutie WJ; Lipworth BJ
Cardiovasc Res; 1997 Jan; 33(1):201-8. PubMed ID: 9059545
[TBL] [Abstract][Full Text] [Related]
10. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.
Hartman JC
Ann Thorac Surg; 1995 Sep; 60(3):789-92. PubMed ID: 7545893
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II receptor antagonist EXP 3174 reduces infarct size comparable with enalaprilat and augments preconditioning in the pig heart.
Schwarz ER; Montino H; Fleischhauer J; Klues HG; vom Dahl J; Hanrath P
Cardiovasc Drugs Ther; 1997 Nov; 11(5):687-95. PubMed ID: 9493708
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of angiotensin II type 1 receptor blockade on reperfusion-induced arrhythmias and mortality early after myocardial infarction is increased in transgenic rats with cardiac angiotensin II type 1 overexpression.
de Boer RA; van Geel PP; Pinto YM; Suurmeijer AJ; Crijns HJ; van Gilst WH; van Veldhuisen DJ
J Cardiovasc Pharmacol; 2002 Apr; 39(4):610-9. PubMed ID: 11904535
[TBL] [Abstract][Full Text] [Related]
13. Effects of NS-2, a new class 1 antiarrhythmic agent, and AFD-19, its active metabolite, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats: comparison with disopyramide and mexiletine.
Komori S; Sawanobori T; Tamura K; Kane KA; Parratt JR
Jpn J Pharmacol; 1994 Jul; 65(3):193-200. PubMed ID: 7799519
[TBL] [Abstract][Full Text] [Related]
14. Survival after myocardial infarction in rats: captopril versus losartan.
Milavetz JJ; Raya TE; Johnson CS; Morkin E; Goldman S
J Am Coll Cardiol; 1996 Mar; 27(3):714-9. PubMed ID: 8606287
[TBL] [Abstract][Full Text] [Related]
15. Effects of dofetilide, a class III antiarrhythmic drug, on various ventricular arrhythmias in dogs.
Chen J; Xue Y; Eto K; Ni C; Hashimoto K
J Cardiovasc Pharmacol; 1996 Oct; 28(4):576-84. PubMed ID: 8891885
[TBL] [Abstract][Full Text] [Related]
16. Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition.
Hartman JC; Hullinger TG; Wall TM; Shebuski RJ
Eur J Pharmacol; 1993 Apr; 234(2-3):229-36. PubMed ID: 8482328
[TBL] [Abstract][Full Text] [Related]
17. Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion.
Thomas GP; Ferrier GR; Howlett SE
J Pharmacol Exp Ther; 1996 Sep; 278(3):1090-7. PubMed ID: 8819490
[TBL] [Abstract][Full Text] [Related]
18. [Angiotensin II antagonist for heart insufficiency].
Z Kardiol; 1997 Jun; 86(6 Suppl):1-8. PubMed ID: 9259867
[No Abstract] [Full Text] [Related]
19. Antiarrhythmic properties of a prior oral loading of amiodarone in in vivo canine coronary ligation/reperfusion-induced arrhythmia model: comparison with other class III antiarrhythmic drugs.
Nagasawa Y; Chen J; Hashimoto K
J Pharmacol Sci; 2005 Mar; 97(3):393-9. PubMed ID: 15764841
[TBL] [Abstract][Full Text] [Related]
20. The potential antiarrhythmic effects of exogenous and endogenous bradykinin in the ischaemic rat heart in vivo.
Sun W; Wainwright CL
Coron Artery Dis; 1994 Jun; 5(6):541-50. PubMed ID: 7952414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
